Upstate Active Clinical Trials
Study Title:Celgene Protocol Number: CC-5013-NHL-007 - A phase 3, double-blind randomized study to compare the efficacy and safety of rituximab plus lenalidomide (cc-5013) versus rituximab plus placebo in subjects with relapsed/refractory indolent lymphoma
What is the purpose of the study?This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Anticipated time on study treatment is 1 year.
Upstate Institutional Review Board (IRB) Number:570813
Patient Age Group:Adults
Principal Investigator:Dorothy C Pan, MD
Who can I contact for more information?
Name: Wendy S Barry